Natural polymeric nanoparticles for brain-targeting: Implications on drug and gene delivery

Current Pharmaceutical Design

Volumn 22, Issue 22, 2016, Pages 3305-3323

  Elzoghby, Ahmed O ^a   Abd Elwakil, Mahmoud M ^a   Abd Elsalam, Kholod ^a   Elsayed, Mustafa T ^a   Hashem, Yosra ^a   Mohamed, Ola ^a  

^a Alexandria University Faculty of Pharmacy   (Egypt)

Author keywords

Brain targeting; Drug delivery; Gene delivery; Glioma; Natural polymers; Polysaccharide nanoparticles; Protein nanoparticles

Indexed keywords

ALBUMIN; ALGINIC ACID; APOLIPOPROTEIN; BOVINE SERUM ALBUMIN; CATIONIC BOVINE SERUM ALBUMIN; CHITOSAN; CISPLATIN; CURCUMIN; CYTOCHROME P450; DENDRIMER; GELATIN; GLYCOL CHITOSAN DEXTRAN SULFATE; HYALURONIC ACID; IRON OXIDE; LACTOFERRIN; NANOCARRIER; NANOCONJUGATE; NEUROTRANSMITTER; PACLITAXEL; POLYAMIDOAMINE; POLYSACCHARIDE; POLYSORBATE 80; PROTEIN; SILK FIBROIN; SMALL INTERFERING RNA; SOLVENT; THIOLATED CHITOSAN; TRANSFERRIN; UNCLASSIFIED DRUG; VENLAFAXINE; ANALGESIC AGENT; ANTINEOPLASTIC AGENT; BIOLOGICAL PRODUCT; DRUG CARRIER; NANOPARTICLE; NEUROPROTECTIVE AGENT; POLYMER; PROTEINASE INHIBITOR;

BLOOD BRAIN BARRIER; BRAIN CELL; BRAIN TUMOR; CROSS LINKING; DEPRESSION; DRUG BINDING; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG TARGETING; DRUG TRANSPORT; DRUG UPTAKE; EMULSION; ENZYME INHIBITION; EPITHELIAL TIGHT JUNCTION; EVAPORATION; GENE DELIVERY SYSTEM; HUMAN; IN VIVO STUDY; INTRANASAL DRUG ADMINISTRATION; NANOEMULSION; NANOENCAPSULATION; NONHUMAN; NOSE MUCOSA; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; THERANOSTIC NANOMEDICINE; TIGHT JUNCTION; TRANSVASCULARGENE DELIVERY; BRAIN; CHEMISTRY; DRUG EFFECTS; METABOLISM;

ANALGESICS; ANTINEOPLASTIC AGENTS; BIOLOGICAL PRODUCTS; BRAIN; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; NANOPARTICLES; NEUROPROTECTIVE AGENTS; POLYMERS; PROTEASE INHIBITORS;

EID: 84975678645     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612822666160204120829     Document Type: Review

References (198)

1. Pardridge WM. Blood-brain barrier biology and methodology. J Neurovirol 1999; 5: 556-69.
2. Abbott NJ, Ronnback L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci 2006; 7: 41-53.
3. Pardridge WM. The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2005; 2: 3-14.
4. Levin VA. Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability. J Med Chem 1980; 23: 682-4.
5. Smith QR, Rapoport SI. Cerebrovascular permeability coefficients to sodium, potassium, and chloride. J Neurochem 1986; 46: 1732-42.
6. del Burgo LS, Hernández RM, Orive G, Pedraz JL. Nanotherapeutic approaches for brain cancer management. Nanomed: Nanotechnol Biol Med 2014; 10: 905-19.
7. Reinhardt RR, Bondy C. Insulin-like growth factors cross the blood-brain barrier. Endocrinology 1994; 135: 1753-61.
8. Golden PL, Maccagnan TJ, Pardridge WM. Human blood-brain barrier leptin receptor. Binding and endocytosis in isolated human brain microvessels. J Clin Invest 1997; 99: 14.
9. Fishman J, Rubin J, Handrahan J, Connor J, Fine R. Receptor-mediated transcytosis of transferrin across the blood-brain barrier. J Neurosci Res 1987; 18: 299-304.
10. Paul W, Sharma C. Chitosan, a drug carrier for the 21st century: a review. STP Pharm Sci 2000; 10: 5-22.
11. Elgindy N, Elkhodairy K, Molokhia A, ElZoghby A. Biopolymeric nanoparticles for oral protein delivery: design and in vitro evaluation. J Nanomed Nanotechnol 2012; 2011.
12. Elgindy N, Elkhodairy K, Molokhia A, Elzoghby A. Lyophilization monophase solution technique for preparation of amorphous flutamide dispersions. Drug Develop Ind Pharm 2011; 37: 754-64.
13. Elgindy N, Elkhodairy K, Molokhia A, Elzoghby A. Lyophilized flutamide dispersions with polyols and amino acids: preparation and in vitro evaluation. Drug Develop Ind Pharm 2011; 37: 446-55.
14. Elzoghby AO, Elgohary MM, Kamel NM. Chapter Six-Implications of Protein-and Peptide-Based Nanoparticles as Potential Vehicles for Anticancer Drugs. Adv Protein Chem Structural Biol 2015; 98: 169-221.
15. Elzoghby AO, Saad NI, Helmy MW, Samy WM, Elgindy NA. Ionically-crosslinked milk protein nanoparticles as flutamide carriers for effective anticancer activity in prostate cancer-bearing rats. Eur J Pharm Biopharm 2013; 85: 444-51.
16. Elzoghby AO, Helmy MW, Samy WM, Elgindy NA. Micellar delivery of flutamide via milk protein nanovehicles enhances its anti-tumor efficacy in androgen-dependent prostate cancer rat model. Pharm Res 2013; 30: 2654-63.
17. Elzoghby AO, Helmy MW, Samy WM, Elgindy NA. Novel ionically crosslinked casein nanoparticles for flutamide delivery: formulation, characterization, and in vivo pharmacokinetics. Int J Nanomed 2013; 8: 1721.
18. Elzoghby AO, Vranic BZ, Samy WM, Elgindy NA. Swellable floating tablet based on spray-dried casein nanoparticles: Nearinfrared spectral characterization and floating matrix evaluation. Int J Pharm 2015; 491: 113-22.
19. Arai K, Kinumaki T, Fujita T. Toxicity of chitosan. Bull Tokai Region Fish Res Lab 1968: 89-94.
20. Patel D, Naik S, Misra A. Improved transnasal transport and brain uptake of tizanidine HCl-loaded thiolated chitosan nanoparticles for alleviation of pain. J Pharm Sci 2012; 101: 690-706.
21. Saboktakin MR, Tabatabaie RM, Maharramov A, Ramazanov MA. Synthesis and characterization of pH-dependent glycol chitosan and dextran sulfate nanoparticles for effective brain cancer treatment. Int J Biol Macromol 2011; 49: 747-51.
22. Di Gioia S, Trapani A, Mandracchia D, et al. Intranasal delivery of dopamine to the striatum using glycol chitosan/sulfobutyletherbeta-cyclodextrin based nanoparticles. Eur J Pharm Biopharm 2015; 94: 180-93.
23. Sood S, Jain K, Gowthamarajan K. Optimization of curcumin nanoemulsion for intranasal delivery using design of experiment and its toxicity assessment. Colloids Surfaces B: Biointerfaces 2014; 113: 330-7.
24. Kumar M, Pathak K, Misra A. Formulation and characterization of nanoemulsion-based drug delivery system of risperidone. Drug Develop Ind Pharm 2009; 35: 387-95.
25. Xie Y-T, Du Y-Z, Yuan H, Hu F-Q. Brain-targeting study of stearic acid–grafted chitosan micelle drug-delivery system. Int J Nanomed 2012; 7: 3235.
26. Lueßen HL, de Leeuw BJ, Langemeÿer MW, de Boer ABG, Verhoef JC, Junginger HE. Mucoadhesive polymers in peroral peptide drug delivery. VI. Carbomer and chitosan improve the intestinal absorption of the peptide drug buserelin in vivo. Pharm Res 1996; 13: 1668-72.
27. Artursson P, Lindmark T, Davis SS, Illum L. Effect of chitosan on the permeability of monolayers of intestinal epithelial cells (Caco-2). Pharm Res 1994; 11: 1358-61.
28. Dodane V, Khan MA, Merwin JR. Effect of chitosan on epithelial permeability and structure. Int J Pharm 1999; 182: 21-32.
29. Chenite A, Gori S, Shive M, Desrosiers E, Buschmann M. Monolithic gelation of chitosan solutions via enzymatic hydrolysis of urea. Carbohydr Polym 2006; 64: 419-24.
30. Illum L. Transport of drugs from the nasal cavity to the central nervous system. Eur J Pharm Sci 2000; 11: 1-18.
31. El-Shabouri M. Positively charged nanoparticles for improving the oral bioavailability of cyclosporin-A. Int J Pharm 2002; 249: 101-8.
32. Chen J, Nagayama T, Jin K, Stetler RA, Zhu RL, Graham SH, Simon RP. Induction of caspase-3-like protease may mediate delayed neuronal death in the hippocampus after transient cerebral ischemia. J Neurosci 1998; 18: 4914-28.
33. Thornberry NA. The caspase family of cysteine proteases. Br Med Bull 1997; 53: 478-90.
34. Aktaş Y, Andrieux K, Alonso MJ, et al. Preparation and in vitro evaluation of chitosan nanoparticles containing a caspase inhibitor. Int J Pharm 2005; 298: 378-83.
35. Aktas Y, Yemisci M, Andrieux K, et al. Development and brain delivery of chitosan-PEG nanoparticles functionalized with the monoclonal antibody OX26. Bioconjug Chem 2005; 16: 1503-11.
36. Wang X, Chi N, Tang X. Preparation of estradiol chitosan nanoparticles for improving nasal absorption and brain targeting. Eur J Pharm Biopharm 2008; 70: 735-40.
37. Mittal D, Md S, Hasan Q, et al. Brain targeted nanoparticulate drug delivery system of rasagiline via intranasal route. Drug Deliv 2014: 1-10.
38. Khan S, Patil K, Yeole P. Intranasal mucoadhesive buspirone formulation: in vitro characterization and nasal clearance studies. Die Pharm Int J Pharm Sci 2008; 63: 348-51.
39. Mustafa G, Ahuja A, Al Rohaimi AH, et al. Nano-ropinirole for the management of Parkinsonism: blood-brain pharmacokinetics and carrier localization. Expt Rev Neurother 2015: 1-16.
40. Kumar M, Misra A, Mishra A, Mishra P, Pathak K. Mucoadhesive nanoemulsion-based intranasal drug delivery system of olanzapine for brain targeting. J Drug Target 2008; 16: 806-14.
41. Kaur P, Garg T, Vaidya B, Prakash A, Rath G, Goyal AK. Brain delivery of intranasal in situ gel of nanoparticulated polymeric carriers containing antidepressant drug: behavioral and biochemical assessment. J Drug Target 2014; 23: 275-86.
42. Patel D, Naik S, Chuttani K, Mathur R, Mishra AK, Misra A. Intranasal delivery of cyclobenzaprine hydrochloride-loaded thiolated chitosan nanoparticles for pain relief. J Drug Target 2013; 21: 759-69.
43. Trapani A, De Giglio E, Cafagna D, et al. Characterization and evaluation of chitosan nanoparticles for dopamine brain delivery. Int J Pharm 2011; 419: 296-307.
44. Kumar M, Pandey RS, Patra KC, et al. Evaluation of neuropeptide loaded trimethyl chitosan nanoparticles for nose to brain delivery. Int J Biol Macromol 2013; 61: 189-95.
45. Posadas I, Guerra FJ, Ceña V. Nonviral vectors for the delivery of small interfering RNAs to the CNS. Nanomedicine 2010; 5: 1219-36.
46. Kim TH, Jiang HL, Nah JW, Cho MH, Akaike T, Cho CS. Receptor-mediated gene delivery using chemically modified chitosan. Biomed Mater 2007; 2: S95-100.
47. Ishii T, Okahata Y, Sato T. Mechanism of cell transfection with plasmid/chitosan complexes. Biochim Biophys Acta (BBA)-Biomembr 2001; 1514: 51-64.
48. Zhang X, Zhang H, Wu Z, Wang Z, Niu H, Li C. Nasal absorption enhancement of insulin using PEG-grafted chitosan nanoparticles. Eur J Pharm Biopharm 2008; 68: 526-34.
49. Csaba N, Köping-Höggård M, Fernandez-Megia E, Novoa-Carballal R, Riguera R, Alonso MJ. Ionically crosslinked chitosan nanoparticles as gene delivery systems: effect of PEGylation degree on in vitro and in vivo gene transfer. J Biomed Nanotechnol 2009; 5: 162-71.
50. Friedman HS, Kerby T, Calvert H. Temozolomide and treatment of malignant glioma. Clin Cancer Res 2000; 6: 2585-97.
51. Danhier F, Messaoudi K, Lemaire L, Benoit J-P, Lagarce F. Combined anti-Galectin-1 and anti-EGFR siRNA-loaded chitosan-lipid nanocapsules decrease temozolomide resistance in glioblastoma: In vivo evaluation. Int J Pharm 2015; 481: 154-61.
52. Kozlu S, Caban S, Yerlikaya F, et al. An aquaporin 4 antisense oligonucleotide loaded, brain targeted nanoparticulate system design. Die Pharm Int J Pharm Sci 2014; 69: 340-5.
53. Wilson B, Samanta MK, Santhi K, Kumar KS, Ramasamy M, Suresh B. Chitosan nanoparticles as a new delivery system for the anti-Alzheimer drug tacrine. Nanomed: Nanotechnol Biol Med 2010; 6: 144-52.
54. Trapani A, Denora N, Iacobellis G, Sitterberg J, Bakowsky U, Kissel T. Methotrexate-loaded chitosan-and glycolchitosan-based nanoparticles: a promising strategy for the administration of the anticancer drug to brain tumors. AAPS PharmSciTech 2011; 12: 1302-11.
55. Agyare EK, Jaruszewski KM, Curran GL, et al. Engineering theranostic nanovehicles capable of targeting cerebrovascular amyloid deposits. J Control Release 2014; 185: 121-9.
56. Stephen ZR, Kievit FM, Veiseh O, et al. Redox-responsive magnetic nanoparticle for targeted convection-enhanced delivery of O 6-benzylguanine to brain tumors. ACS Nano 2014; 8: 10383-95.
57. Platt VM, Szoka Jr FC. Anticancer therapeutics: targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor. Mol Pharm 2008; 5: 474-86.
58. Jaracz S, Chen J, Kuznetsova LV, Ojima I. Recent advances in tumor-targeting anticancer drug conjugates. Bioorg Med Chem 2005; 13: 5043-54.
59. Vercruysse KP, Prestwich GD. Hyaluronate derivatives in drug delivery. Crit Rev Therap Drug Carrier Syst 1998; 15.
60. Rosato A, Banzato A, De Luca G, et al. HYTAD1-p20: a new paclitaxel-hyaluronic acid hydrosoluble bioconjugate for treatment of superficial bladder cancer. Urol Oncol 2006; 24(3): 207-15.
61. Banzato A, Bobisse S, Rondina M, et al. A paclitaxel-hyaluronan bioconjugate targeting ovarian cancer affords a potent in vivo therapeutic activity. Clin Cancer Res 2008; 14: 3598-606.
62. Yoon HY, Koo H, Choi KY, et al. Photo-crosslinked hyaluronic acid nanoparticles with improved stability for in vivo tumortargeted drug delivery. Biomaterials 2013; 34: 5273-80.
63. Yang X-Y, Li Y-X, Li M, Zhang L, Feng LX, Zhang N. Hyaluronic acid-coated nanostructured lipid carriers for targeting paclitaxel to cancer. Cancer Lett 2013; 334: 338-45.
64. Das M, Singh RP, Datir SR, Jain S. Surface chemistry dependent “switch” regulates the trafficking and therapeutic performance of drug-loaded carbon nanotubes. Bioconjug Chem 2013; 24: 626-39.
65. Jin YJ, Termsarasab U, Ko SH, et al. Hyaluronic acid derivativebased self-assembled nanoparticles for the treatment of melanoma. Pharm Res 2012; 29: 3443-54.
66. Singh SK, Clarke ID, Hide T, Dirks PB. Cancer stem cells in nervous system tumors. Oncogene 2004; 23: 7267-73.
67. Jordan CT, Guzman ML. Mechanisms controlling pathogenesis and survival of leukemic stem cells. Oncogene 2004; 23: 7178-87.
68. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100: 3983-8.
69. Al-Hajj M, Clarke MF. Self-renewal and solid tumor stem cells. Oncogene 2004; 23: 7274-82.
70. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. nature 2001; 414: 105-11.
71. Mittapalli RK, Liu X, Adkins CE, et al. Paclitaxel-hyaluronic nanoconjugates prolong overall survival in a preclinical brain metastases of breast cancer model. Mol Cancer Ther 2013; 12: 2389-99.
72. Jeong YI, Kim ST, Jin SG, et al. Cisplatin-incorporated hyaluronic acid nanoparticles based on ion-complex formation. J Pharm Sci 2008; 97: 1268-76.
73. Yang L, Gao S, Asghar S, et al. Hyaluronic acid/chitosan nanoparticles for delivery of curcuminoid and its in vitro evaluation in glioma cells. Int J Biol Macromol 2015; 72: 1391-401.
74. Robitzer M, Quignard F. Marine polysaccharides and their conversion into functional materials. CHIMIA Int J Chemy 2011; 65: 81-4.
75. Iskakov RM, Kikuchi A, Okano T. Time-programmed pulsatile release of dextran from calcium-alginate gel beads coated with carboxy-n-propylacrylamide copolymers. J Control Release 2002; 80: 57-68.
76. Shimizu T, Yamato M, Kikuchi A, Okano T. Cell sheet engineering for myocardial tissue reconstruction. Biomaterials 2003; 24: 2309-16.
77. Haque S, Md S, Sahni JK, Ali J, Baboota S. Development and evaluation of brain targeted intranasal alginate nanoparticles for treatment of depression. J Psychiatr Res 2014; 48: 1-12.
78. Siddique YH, Khan W, Singh BR, Naqvi AH. Synthesis of alginate-curcumin nanocomposite and its protective role in transgenic Drosophila model of Parkinson's disease. ISRN Pharmacol 2013; 2013: 794582.
79. Chavanpatil MD, Khdair A, Gerard B, et al. Surfactant-polymer nanoparticles overcome P-glycoprotein-mediated drug efflux. Mol Pharm 2007; 4: 730-8.
80. Mishra V, Mahor S, Rawat A, et al. Targeted brain delivery of AZT via transferrin anchored pegylated albumin nanoparticles. J Drug Target 2006; 14: 45-53.
81. Nakagawa Y, Takayama K, Ueda H, Machida Y, Nagai T. Preparation of bovine serum albumin nanospheres as drug targeting carriers. Drug Des Deliv 1987; 2: 99-107.
82. Anhorn MG, Wagner S, Kreuter J, Langer K, von Briesen H. Specific targeting of HER2 overexpressing breast cancer cells with doxorubicin-loaded trastuzumab-modified human serum albumin nanoparticles. Bioconjug Chem 2008; 19: 2321-31.
83. Su Z, Xing L, Chen Y, et al. Lactoferrin-modified poly(ethylene glycol)-grafted BSA nanoparticles as a dual-targeting carrier for treating brain gliomas. Mol Pharm 2014; 11: 1823-34.
84. Luppi B, Bigucci F, Corace G, et al. Albumin nanoparticles carrying cyclodextrins for nasal delivery of the anti-Alzheimer drug tacrine. Eur J Pharm Sci 2011; 44: 559-65.
85. Lu W, Zhang Y, Tan YZ, Hu KL, Jiang XG, Fu SK. Cationic albumin-conjugated pegylated nanoparticles as novel drug carrier for brain delivery. J Control Release 2005; 107: 428-48.
86. Gonatas NK, Stieber A, Hickey WF, Herbert SH, Gonatas JO. Endosomes and Golgi vesicles in adsorptive and fluid phase endocytosis. J Cell Biol 1984; 99: 1379-90.
87. Panyam J, Labhasetwar V. Dynamics of endocytosis and exocytosis of poly(D,L-lactide-co-glycolide) nanoparticles in vascular smooth muscle cells. Pharm Res 2003; 20: 212-20.
88. Griffin DE, Giffels J. Study of protein characteristics that influence entry into the cerebrospinal fluid of normal mice and mice with encephalitis. J Clin Invest 1982; 70: 289-95.
89. Bickel U, Yoshikawa T, Pardridge WM. Delivery of peptides and proteins through the blood-brain barrier. Adv Drug Deliv Rev 2001; 46: 247-79.
90. Triguero D, Buciak J, Pardridge WM. Capillary depletion method for quantification of blood-brain barrier transport of circulating peptides and plasma proteins. J Neurochem 1990; 54: 1882-8.
91. Xie YL, Lu W, Jiang XG. Improvement of cationic albumin conjugated pegylated nanoparticles holding NC-1900, a vasopressin fragment analog, in memory deficits induced by scopolamine in mice. Behav Brain Res 2006; 173: 76-84.
92. Lu W, Tan YZ, Hu KL, Jiang XG. Cationic albumin conjugated pegylated nanoparticle with its transcytosis ability and little toxicity against blood-brain barrier. Int J Pharm 2005; 295: 247-60.
93. Wilson B, Lavanya Y, Priyadarshini SR, Ramasamy M, Jenita JL. Albumin nanoparticles for the delivery of gabapentin: preparation, characterization and pharmacodynamic studies. Int J Pharm 2014; 473: 73-9.
94. Friese A, Seiller E, Quack G, Lorenz B, Kreuter J. Increase of the duration of the anticonvulsive activity of a novel NMDA receptor antagonist using poly(butylcyanoacrylate) nanoparticles as a parenteral controlled release system. Eur J Pharm Biopharm 2000; 49: 103-9.
95. Ulbrich K, Hekmatara T, Herbert E, Kreuter J. Transferrin-and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB). Eur J Pharm Biopharm 2009; 71: 251-6.
96. Zensi A, Begley D, Pontikis C, et al. Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurones. J Control Release 2009; 137: 78-86.
97. Michaelis K, Hoffmann MM, Dreis S, et al. Covalent linkage of apolipoprotein e to albumin nanoparticles strongly enhances drug transport into the brain. J Pharmacol Exp Ther 2006; 317: 1246-53.
98. Joachim E, Kim ID, Jin Y, Kim KK, Lee JK, Choi H. Gelatin nanoparticles enhance the neuroprotective effects of intranasally administered osteopontin in rat ischemic stroke model. Drug Deliv Transl Res 2014; 4: 395-9.
99. Lucivero V, Prontera M, Mezzapesa DM, et al. Different roles of matrix metalloproteinases-2 and-9 after human ischaemic stroke. Neurol Sci 2007; 28: 165-70.
100. Alam MI, Baboota S, Ahuja A, Ali M, Ali J, Sahni JK. Intranasal administration of nanostructured lipid carriers containing CNS acting drug: pharmacodynamic studies and estimation in blood and brain. J Psychiatr Res 2012; 46: 1133-8.
101. Chen J, Zhang C, Liu Q, et al. Solanum tuberosum lectinconjugated PLGA nanoparticles for nose-to-brain delivery: in vivo and in vitro evaluations. J Drug Target 2012; 20: 174-84.
102. Sivera M, Kvitek L, Soukupova J, et al. Silver nanoparticles modified by gelatin with extraordinary pH stability and long-term antibacterial activity. PLoS One 2014; 9: e103675.
103. Lee SJ, Yhee JY, Kim SH, Kwon IC, Kim K. Biocompatible gelatin nanoparticles for tumor-targeted delivery of polymerized siRNA in tumor-bearing mice. J Control Release 2013; 172: 358-66.
104. Jin Y, Kim IY, Kim ID, et al. Biodegradable gelatin microspheres enhance the neuroprotective potency of osteopontin via quick and sustained release in the post-ischemic brain. Acta Biomater 2014; 10: 3126-35.
105. Cheng F, Choy YB, Choi H, Kim K. Modeling of small-molecule release from crosslinked hydrogel microspheres: Effect of crosslinking and enzymatic degradation of hydrogel matrix. Int J Pharm 2011; 403: 90-5.
106. Jahanshahi M, Sanati MH, Hajizadeh S, Babaei Z. Gelatin nanoparticle fabrication and optimization of the particle size. Phys Status Solid (a) 2008; 205: 2898-902.
107. Lu CT, Jin RR, Jiang YN, et al. Gelatin nanoparticle-mediated intranasal delivery of substance P protects against 6-hydroxydopamine-induced apoptosis: an in vitro and in vivo study. Drug Des Develop Ther 2015; 9: 1955-62.
108. Tian XH, Wei F, Wang TX, et al. Blood–brain barrier transport of Tat peptide and polyethylene glycol decorated gelatin–siloxane nanoparticle. Mater Lett 2012; 68: 94-6.
109. Drin G, Cottin S, Blanc E, Rees AR, Temsamani J. Studies on the internalization mechanism of cationic cell-penetrating peptides. J Biol Chem 2003; 278: 31192-201.
110. Tian XH, Wei F, Wang TX, et al. In vitro and in vivo studies on gelatin-siloxane nanoparticles conjugated with SynB peptide to increase drug delivery to the brain. Int J Nanomed 2012; 7: 1031-41.
111. Tian XH, Wang ZG, Meng H, et al. Tat peptide-decorated gelatinsiloxane nanoparticles for delivery of CGRP transgene in treatment of cerebral vasospasm. Int J Nanomed 2013; 8: 865-76.
112. Gabathuler R. Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases. Neurobiol Dis 2010; 37: 48-57.
113. Wang ZY, Zhao Y, Ren L, et al. Novel gelatin-siloxane nanoparticles decorated by Tat peptide as vectors for gene therapy. Nanotechnology 2008; 19: 445103.
114. Xu ZP, Zeng QH, Lu GQ, Yu AB. Inorganic nanoparticles as carriers for efficient cellular delivery. Chem Eng Sci 2006; 61: 1027-40.
115. Gomme PT, McCann KB, Bertolini J. Transferrin: structure, function and potential therapeutic actions. Drug Discov Today 2005; 10: 267-73.
116. Li H, Qian ZM. Transferrin/transferrin receptor-mediated drug delivery. Med Res Rev 2002; 22: 225-50.
117. Cabral Filho PE, Cardoso AL, Pereira MI, et al. CdTe quantum dots as fluorescent probes to study transferrin receptors in glioblastoma cells. Biochim Biophys Acta (BBA)-General Subjects 2016; 1860: 28-35.
118. Wang Y-Y, Lui PC, Li JY. Receptor-mediated therapeutic transport across the blood-brain barrier. Immunotherapy 2009; 1: 983-93.
119. Huwyler J, Cerletti A, Fricker G, Eberle AN, Drewe J. By-passing of P-glycoprotein using immunoliposomes. J Drug Target 2002; 10: 73-9.
120. Lv Q, Li LM, Han M, et al. Characteristics of sequential targeting of brain glioma for transferrin-modified cisplatin liposome. Int J Pharm 2013; 444: 1-9.
121. Kobayashi T, Ishida T, Okada Y, Ise S, Harashima H, Kiwada H. Effect of transferrin receptor-targeted liposomal doxorubicin in Pglycoprotein-mediated drug resistant tumor cells. Int J Pharm 2007; 329: 94-102.
122. Zheng C, Ma C, Bai E, Yang K, Xu R. Transferrin and cellpenetrating peptide dual-functioned liposome for targeted drug delivery to glioma. Int J Clin Exp Med 2015; 8: 1658.
123. Wang Z, Zhao Y, Jiang Y, et al. Enhanced anti-ischemic stroke of ZL006 by T7-conjugated PEGylated liposomes drug delivery system. Sci Rep 2015; 5: 12651.
124. Soni V, Kohli D, Jain S. Transferrin-conjugated liposomal system for improved delivery of 5-fluorouracil to brain. J Drug Target 2008; 16: 73-8.
125. Prabhakar K, Afzal SM, Kumar PU, Rajanna A, Kishan V. Brain delivery of transferrin coupled indinavir submicron lipid emulsions— Pharmacokinetics and tissue distribution. Colloids Surf B: Biointerfaces 2011; 86: 305-13.
126. Gupta Y, Jain A, Jain SK. Transferrin-conjugated solid lipid nanoparticles for enhanced delivery of quinine dihydrochloride to the brain. J Pharm Pharmacol 2007; 59: 935-40.
127. Kuo YC, Wang LJ. Transferrin-grafted catanionic solid lipid nanoparticles for targeting delivery of saquinavir to the brain. J Taiwan Inst Chem Eng 2014; 45: 755-63.
128. Gan CW, Feng S-S. Transferrin-conjugated nanoparticles of poly (lactide)-D-α-tocopheryl polyethylene glycol succinate diblock copolymer for targeted drug delivery across the blood–brain barrier. Biomaterials 2010; 31: 7748-57.
129. Guo W, Li A, Jia Z, Yuan Y, Dai H, Li H. Transferrin modified PEG-PLA-resveratrol conjugates: In vitro and in vivo studies for glioma. Eur J Pharmacol 2013; 718: 41-7.
130. Kuo Y-C, Lin P-I, Wang C-C. Targeting nevirapine delivery across human brain microvascular endothelial cells using transferringrafted poly (lactide-co-glycolide) nanoparticles. Nanomedicine 2011; 6: 1011-26.
131. Jain A, Chasoo G, Singh SK, Saxena AK, Jain SK. Transferrinappended PEGylated nanoparticles for temozolomide delivery to brain: in vitro characterisation. J Microencapsul 2011; 28: 21-28.
132. Sonali, Agrawal P, Singh RP, et al. Transferrin receptor-targeted vitamin E TPGS micelles for brain cancer therapy: preparation, characterization and brain distribution in rats. Drug Deliv 2015: 1-11.
133. Wei X, Chen X, Ying M, Lu W. Brain tumor-targeted drug delivery strategies. Acta Pharm Sin B 2014; 4: 193-201.
134. Li Y, He H, Jia X, Lu W-L, Lou J, Wei Y. A dual-targeting nanocarrier based on poly (amidoamine) dendrimers conjugated with transferrin and tamoxifen for treating brain gliomas. Biomaterials 2012; 33: 3899-908.
135. Huang RQ, Qu YH, Ke WL, Zhu JH, Pei YY, Jiang C. Efficient gene delivery targeted to the brain using a transferrin-conjugated polyethyleneglycol-modified polyamidoamine dendrimer. FASEB J 2007; 21: 1117-1125.
136. Somani S, Blatchford DR, Millington O, Stevenson ML, Dufès C. Transferrin-bearing polypropylenimine dendrimer for targeted gene delivery to the brain. J Control Release 2014; 188: 78-86.
137. Yan F, Wang Y, He S, Ku S, Gu W, Ye L. Transferrin-conjugated, fluorescein-loaded magnetic nanoparticles for targeted delivery across the blood–brain barrier. J Mater Sci: Mater Med 2013; 24: 2371-2379.
138. Cui Y, Xu Q, Chow PK, Wang D, Wang CH. Transferrinconjugated magnetic silica PLGA nanoparticles loaded with doxorubicin and paclitaxel for brain glioma treatment. Biomaterials 2013; 34: 8511-20.
139. Dixit S, Novak T, Miller K, Zhu Y, Kenney ME, Broome A-M. Transferrin receptor-targeted theranostic gold nanoparticles for photosensitizer delivery in brain tumors. Nanoscale 2015; 7: 1782-90.
140. Dixit S, Miller K, Zhu Y, et al. Dual receptor-targeted theranostic nanoparticles for localized delivery and activation of photodynamic therapy drug in glioblastomas. Mol Pharm 2015; 12: 3250-60.
141. Zhang P, Hu L, Yin Q, Zhang Z, Feng L, Li Y. Transferrinconjugated polyphosphoester hybrid micelle loading paclitaxel for brain-targeting delivery: synthesis, preparation and in vivo evaluation. J Control Release 2012; 159: 429-34.
142. Kayyali R, Marriott C, Wiseman H. Tamoxifen decreases drug efflux from liposomes: relevance to its ability to reverse multidrug resistance in cancer cells? FEBS Lett 1994; 344: 221-4.
143. Ying X, Wen H, Lu W-L, et al. Dual-targeting daunorubicin liposomes improve the therapeutic efficacy of brain glioma in animals. J Control Release 2010; 141: 183-92.
144. Friden PM, Walus LR, Musso GF, Taylor MA, Malfroy B, Starzyk RM. Anti-transferrin receptor antibody and antibody-drug conjugates cross the blood-brain barrier. Proc Natl Acad Sci 1991; 88: 4771-5.
145. Clark AJ, Davis ME. Increased brain uptake of targeted nanoparticles by adding an acid-cleavable linkage between transferrin and the nanoparticle core. Proc Natl Acad Sci USA 2015; 112: 12486-91.
146. Huwyler J, Wu D, Pardridge WM. Brain drug delivery of small molecules using immunoliposomes. Proc Natl Acad Sci USA 1996; 93: 14164-14169.
147. Vogel HJ. Lactoferrin, a bird's eye view. Biochem Cell Biol 2012; 90: 233-44.
148. Miao D, Jiang M, Liu Z, et al. Co-administration of dual-targeting nanoparticles with penetration enhancement peptide for antiglioblastoma therapy. Mol Pharm 2014; 11: 90-101.
149. Spik G, Legrand D, Leveugle B, et al. Characterization of two kinds of lactotransferrin (lactoferrin) receptors on different target cells. Adv Exp Med Biol 1994; 357: 13-9.
150. Strickland DK, Gonias SL, Argraves WS. Diverse roles for the LDL receptor family. Trends Endocrinol Metab 2002; 13: 66-74.
151. Willnow TE, Goldstein JL, Orth K, Brown MS, Herz J. Low density lipoprotein receptor-related protein and gp330 bind similar ligands, including plasminogen activator-inhibitor complexes and lactoferrin, an inhibitor of chylomicron remnant clearance. J Biol Chem 1992; 267: 26172-80.
152. Hu K, Shi Y, Jiang W, Han J, Huang S, Jiang X. Lactoferrin conjugated PEG-PLGA nanoparticles for brain delivery: Preparation, characterization and efficacy in Parkinson's disease. Int J Pharm 2011; 415: 273-83.
153. Qian ZM, Wang Q. Expression of iron transport proteins and excessive iron accumulation in the brain in neurodegenerative disorders. Brain Res Brain Res Rev 1998; 27: 257-67.
154. Kuo Y-C, Chen Y-C. Targeting delivery of etoposide to inhibit the growth of human glioblastoma multiforme using lactoferrin-and folic acid-grafted poly(lactide-co-glycolide) nanoparticles. Int J Pharm 2015; 479: 138-49.
155. Bhardwaj V, Ankola DD, Gupta SC, Schneider M, Lehr CM, Kumar MNVR. PLGA nanoparticles stabilized with cationic surfactant: safety studies and application in oral delivery of paclitaxel to treat chemical-induced breast cancer in rat. Pharm Res 2009; 26: 2495-503.
156. Rupert LAM, Hoekstra D, Engberts JBFN. Fusogenic behavior of didodecyldimethylammonium bromide bilayer vesicles. J Am Chem Soc 1985; 107: 2628-31.
157. Huang R, Ke W, Han L, et al. Brain-targeting mechanisms of lactoferrin-modified DNA-loaded nanoparticles. J Cereb Blood Flow Metab 2009; 29: 1914-23.
158. Chen H, Tang L, Qin Y, et al. Lactoferrin-modified procationic liposomes as a novel drug carrier for brain delivery. Eur J Pharm Sci 2010; 40: 94-102.
159. Ji B, Maeda J, Higuchi M, et al. Pharmacokinetics and brain uptake of lactoferrin in rats. Life Sci 2006; 78: 851-5.
160. Letchford K, Burt H. A review of the formation and classification of amphiphilic block copolymer nanoparticulate structures: micelles, nanospheres, nanocapsules and polymersomes. Eur J Pharm Biopharm 2007; 65: 259-69.
161. Fillebeen C, Descamps L, Dehouck MP, et al. Receptor-mediated transcytosis of lactoferrin through the blood-brain barrier. J Biol Chem 1999; 274: 7011-7.
162. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000; 65: 271-84.
163. Pang Z, Feng L, Hua R, et al. Lactoferrin-conjugated biodegradable polymersome holding doxorubicin and tetrandrine for chemotherapy of glioma rats. Mol Pharm 2010; 7: 1995-2005.
164. Liu Z, Jiang M, Kang T, et al. Lactoferrin-modified PEG-co-PCL nanoparticles for enhanced brain delivery of NAP peptide following intranasal administration. Biomaterials 2013; 34: 3870-81.
165. Hu K, Li J, Shen Y, et al. Lactoferrin-conjugated PEG-PLA nanoparticles with improved brain delivery: in vitro and in vivo evaluations. J Control Release 2009; 134: 55-61.
166. Xie H, Zhu Y, Jiang W, et al. Lactoferrin-conjugated superparamagnetic iron oxide nanoparticles as a specific MRI contrast agent for detection of brain glioma in vivo. Biomaterials 2011; 32: 495-502.
167. Jiang L, Zhou Q, Mu K, et al. pH/temperature sensitive magnetic nanogels conjugated with Cy5.5-labled lactoferrin for MR and fluorescence imaging of glioma in rats. Biomaterials 2013; 34: 7418-28.
168. Xiong W, Gao X, Zhao Y, Xu H, Yang X. The dual temperature/ pH-sensitive multiphase behavior of poly(Nisopropylacrylamide-co-acrylic acid) microgels for potential application in in situ gelling system. Colloids Surf B: Biointerfaces 2011; 84: 103-10.
169. Xiong W, Wang W, Wang Y, et al. Dual temperature/pH-sensitive drug delivery of poly(N-isopropylacrylamide-co-acrylic acid) nanogels conjugated with doxorubicin for potential application in tumor hyperthermia therapy. Colloids and Surfaces B: Biointerfaces 2011; 84: 447-53.
170. Yoo J-W, Doshi N, Mitragotri S. Adaptive micro and nanoparticles: Temporal control over carrier properties to facilitate drug delivery. Adv Drug Deliv Rev 2011; 63: 1247-56.
171. Huang R, Ke W, Liu Y, Jiang C, Pei Y. The use of lactoferrin as a ligand for targeting the polyamidoamine-based gene delivery system to the brain. Biomaterials 2008; 29: 238-46.
172. Huang R, Han L, Li J, et al. Neuroprotection in a 6-hydroxydopamine-lesioned Parkinson model using lactoferrinmodified nanoparticles. J Gene Med 2009; 11: 754-63.
173. Kasoju N, Bora U. Silk fibroin in tissue engineering. Adv Healthc Mater 2012; 1: 393-412.
174. Wang C-Y, Zhang KH, Fan CY, Mo XM, Ruan HJ, Li FF. Aligned natural–synthetic polyblend nanofibers for peripheral nerve regeneration. Acta Biomater 2011; 7: 634-43.
175. Hu Y-L, Gao J-Q. Potential neurotoxicity of nanoparticles. Int J Pharm 2010; 394: 115-21.
176. Deng M, Huang Z, Zou Y, Yin G, Liu J, Gu J. Fabrication and neuron cytocompatibility of iron oxide nanoparticles coated with silk-fibroin peptides. Colloids Surf B: Biointerfaces 2014; 116: 465-71.
177. Alam S, Khan ZI, Mustafa G, et al. Development and evaluation of thymoquinone-encapsulated chitosan nanoparticles for nose-tobrain targeting: a pharmacoscintigraphic study. Int J Nanomed 2012; 7: 5705-18.
178. Bhavna, Md S, Ali M, Ali R, Bhatnagar A, Baboota S, Ali J. Donepezil nanosuspension intended for nose to brain targeting: In vitro and in vivo safety evaluation. Int J Biol Macromol 2014; 67: 418-25.
179. Fazil M, Md S, Haque S, et al. Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting. Eur J Pharm Sci 2012; 47: 6-15.
180. Elnaggar YS, Etman SM, Abdelmonsif DA, Abdallah OY. Intranasal piperine-loaded chitosan nanoparticles as brain-targeted therapy in alzheimer's disease: optimization, biological efficacy, and potential toxicity. J Pharm Sci 2015; 104: 3544-56.
181. Khan S, Patil K, Yeole P, Gaikwad R. Brain targeting studies on buspirone hydrochloride after intranasal administration of mucoadhesive formulation in rats. J Pharm Pharmacol 2009; 61: 669-75.
182. Haque S, Md S, Fazil M, et al. Venlafaxine loaded chitosan NPs for brain targeting: pharmacokinetic and pharmacodynamic evaluation. Carbohydr Polym 2012; 89: 72-9.
183. Md S, Haque S, Fazil M, et al. Optimised nanoformulation of bromocriptine for direct nose-to-brain delivery: biodistribution, pharmacokinetic and dopamine estimation by ultra-HPLC/mass spectrometry method. Expert Opin Drug Deliv 2014; 11: 827-42.
184. Gulati N, Nagaich U, Saraf SA. Intranasal delivery of chitosan nanoparticles for migraine therapy. Sci Pharm 2013; 81: 843-54.
185. Al-Ghananeem AM, Saeed H, Florence R, Yokel RA, Malkawi AH. Intranasal drug delivery of didanosine-loaded chitosan nanoparticles for brain targeting; an attractive route against infections caused by AIDS viruses. J Drug Target 2010; 18: 381-8.
186. Azadi A, Hamidi M, Khoshayand MR, Amini M, Rouini MR. Preparation and optimization of surface-treated methotrexateloaded nanogels intended for brain delivery. Carbohydr Polym 2012; 90: 462-71.
187. Ramalingam P, Ko YT. Enhanced oral delivery of curcumin from N-trimethyl chitosan surface-modified solid lipid nanoparticles: pharmacokinetic and brain distribution evaluations. Pharm Res 2015; 32: 389-402.
188. Dadparvar M, Wagner S, Wien S, et al. HI 6 human serum albumin nanoparticles—Development and transport over an in vitro blood– brain barrier model. Toxicol Lett 2011; 206: 60-6.
189. Ye Y, Sun Y, Zhao H, et al. A novel lactoferrin-modified α-cyclodextrin nanocarrier for brain-targeting drug delivery. Int J Pharm 2013; 458: 110-7.
190. Kamalinia G, Khodagholi F, Atyabi F, et al. Enhanced brain delivery of deferasirox–lactoferrin conjugates for iron chelation therapy in neurodegenerative disorders: in vitro and in vivo studies. Mol Pharm 2013; 10: 4418-31.
191. Chen H, Qin Y, Zhang Q, et al. Lactoferrin modified doxorubicinloaded procationic liposomes for the treatment of gliomas. Eur J Pharm Sci 2011; 44: 164-73.
192. Yu Y, Pang Z, Lu W, Yin Q, Gao H, Jiang X. Self-assembled polymersomes conjugated with lactoferrin as novel drug carrier for brain delivery. Pharm Res 2012; 29: 83-96.
193. Zheng S, Xie Y, Li Y, et al. Development of high drug-loading nanomicelles targeting steroids to the brain. Int J Nanomed 2014; 9: 55.
194. Su Z, Xing L, Chen Y, et al. Lactoferrin-modified poly (ethylene glycol)-grafted BSA nanoparticles as a dual-targeting carrier for treating brain gliomas. Mol Pharm 2014; 11: 1823-34.
195. Zhou Q, Mu K, Jiang L, et al. glioma-targeting micelles for optical/ magnetic resonance dual-mode imaging. Int J Nanomed 2015; 10: 1805.
196. De Luca MA, Lai F, Corrias F, et al. Lactoferrin-and antitransferrin-modified liposomes for brain targeting of the NK3 receptor agonist senktide: Preparation and in vivo evaluation. Int J Pharm 2015; 479: 129-37.
197. Huang R, Ke W, Han L, et al. Lactoferrin-modified nanoparticles could mediate efficient gene delivery to the brain in vivo. Brain Res Bull 2010; 81: 600-4.
198. Huang F-YJ, Chen W-J, Lee W-Y, Lo S-T, Lee T-W, Lo J-M. In vitro and in vivo evaluation of lactoferrin-conjugated liposomes as a novel carrier to improve the brain delivery. Int J Mol Sci 2013; 14: 2862-74.